<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="128">
  <stage>Registered</stage>
  <submitdate>2/11/1999</submitdate>
  <approvaldate>2/11/1999</approvaldate>
  <nctid>NCT00002001</nctid>
  <trial_identification>
    <studytitle>The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease</studytitle>
    <scientifictitle>The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>02</secondaryid>
    <secondaryid>052B</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Zidovudine
Treatment: drugs - Zalcitabine
Treatment: drugs - Didanosine

Treatment: drugs: Zidovudine


Treatment: drugs: Zalcitabine


Treatment: drugs: Didanosine


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Patients with PCP may be randomized to study medication after contacting the sponsor
             and following a minimum 7-day course of therapy resulting in stabilization of their
             disease. Patients with stabilized disease must have fever &lt; 39 C for at least 48
             hours, p02 (on room air) &gt; or = 60 mm and an A/A gradient &lt; or = 30 mm.

          -  Prophylaxis for PCP.

        Patients must have the following:

          -  HIV-1 seropositive by any federally licensed ELISA.

          -  Willingness to give informed consent.</inclusivecriteria>
    <inclusiveminage>13</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Any immediately life-threatening infection or medical condition present at time of
             study entry.

          -  Any active opportunistic infection requiring chronic therapy with any of the agents
             listed in the exclusion concurrent medication section.

          -  Neoplasms other than basal cell carcinoma or in situ carcinoma of the cervix.

          -  Kaposi's sarcoma with visceral involvement or requiring systemic cytotoxic
             chemotherapy.

          -  AIDS dementia complex, &gt; or = Stage 2.

          -  History of zidovudine induced toxicity.

          -  Prior history of acute pancreatitis during the past two years or chronic pancreatitis.

          -  Grade 2 neuropathy.

          -  Intractable diarrhea.

          -  History of seizures within the past six months or current requirement of
             anticonvulsants.

          -  Past or current heart disease.

          -  Fever &gt; 39 C at entry.

        Concurrent Medication:

        Current requirement of anticonvulsants.

          -  Excluded:

          -  It is intended that patients developing new opportunistic infections during the course
             of the study will continue study participation, unless required therapy is associated
             with significant neurologic or hematologic toxicities, in which case the study
             medication may be temporarily discontinued.

          -  Ganciclovir.

          -  Chloramphenicol.

          -  Cisplatinum.

          -  Iodoquinol.

          -  Systemic Pentamidine.

          -  Disulfiram.

          -  Ethionamide.

          -  Glutethimide.

          -  Gold.

          -  Hydralazine.

          -  Metronidazole.

          -  Sodium Cyanate.

          -  Thalidomide.

          -  Vincristine.

          -  Allopurinol.

          -  Probenecid.

        Concurrent Treatment:

        Excluded:

          -  Radiation therapy. (with the exception of electron beam therapy to an area of &lt;
             100cm/m2.)

        Patients with the following are excluded:

          -  Any immediately life-threatening infection or medical condition present at time of
             study entry.

          -  Any active opportunistic infection requiring chronic therapy with any of the agents
             listed in the exclusion concurrent medication section.

          -  Active alcohol or drug abuse, sufficient in the investigator's opinion to prevent
             compliance with study therapy.

          -  Neoplasms other than basal cell carcinoma or in situ carcinoma of the cervix.

          -  Kaposi's syndrome with visceral involvement or requiring systemic cytotoxic
             chemotherapy.

          -  AIDS dementia complex, &gt; or = Stage 2.

          -  History of zidovudine induced toxicity.

          -  Any experimental therapy within 30 days.

          -  Prior history of acute pancreatitis during the past two years or chronic pancreatitis.

          -  Grade 2 neuropathy.

          -  Intractable diarrhea.

          -  History of seizures within the past six months or current requirement of
             anticonvulsants.

          -  History of past or current heart disease.

          -  Fever &gt; 39 C at entry.

        Prior Medication:

        Excluded:

          -  Any anti-HIV therapy (other than zidovudine), biologic response modifiers, or
             pharmacologic doses of corticosteroids within eight weeks of entry (except for the
             management of severe PCP, in which case duration is not to exceed 21 days).

          -  Zidovudine therapy for greater than four weeks or prior discontinuation due to drug
             toxicity.

          -  Prior therapy with ddI, ddC, D4T, or interferon.

          -  Any experimental therapy within 30 days.

          -  Therapy within 30 days with neurotoxic drugs.

        Prior Treatment:

        Excluded:

          -  Radiation therapy within two weeks of entry or likely to require radiation therapy
             (with the exception of electron beam therapy to an area of &lt; 100cm/m2).

        Active alcohol or drug abuse, sufficient in the investigator's opinion, to prevent
        compliance with study therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Saint Vincent's Hosp Med Centre - Darlinghurst</hospital>
    <postcode> - Darlinghurst</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Glaxo Wellcome</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the virologic effect of combined administration of zidovudine and ddI or ddC. To
      evaluate the immunologic effects of zidovudine and ddI or ddC. To evaluate combined
      administration of zidovudine and ddI or ddC for clinical efficacy. To evaluate the safety and
      the tolerance of the coadministration of zidovudine and ddI or ddC.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00002001</trialwebsite>
    <publication>Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group. J Virol. 1996 Sep;70(9):5922-9.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>